OtherConference Proceeding

Adventitious Agents: Issues and Considerations during Pre-Approval Reviews and Inspections

John Eltermann
PDA Journal of Pharmaceutical Science and Technology November 2011, 65 (6) 694-697; DOI: https://doi.org/10.5731/pdajpst.2011.00845

Article Information

vol. 65 no. 6 694-697
DOI 
https://doi.org/10.5731/pdajpst.2011.00845
PubMed 
22294603
Published By 
Parenteral Drug Association (PDA)
Print ISSN 
1079-7440
Online ISSN 
1948-2124
History 
  • Published online January 4, 2012.
Copyright & Usage 
© PDA, Inc. 2011

Author Information

  1. John Eltermann
  1. Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD
  1. John Eltermann, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852. E-mail: john.eltermann{at}fda.hhs.gov.
View Full Text

Cited By...

Back to top

In This Issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Adventitious Agents: Issues and Considerations during Pre-Approval Reviews and Inspections
John Eltermann
PDA Journal of Pharmaceutical Science and Technology Nov 2011, 65 (6) 694-697; DOI: 10.5731/pdajpst.2011.00845
Twitter logo Facebook logo Mendeley logo

Jump to section